Photo from wikipedia
Efmoroctocog alfa, the first recombinant factor VIII fusion protein with extended half‐life (rFVIII‐Fc), has been hypothesized to lower FVIII consumption in patients with severe Haemophilia A (pwSHA), without reducing clinical… Click to show full abstract
Efmoroctocog alfa, the first recombinant factor VIII fusion protein with extended half‐life (rFVIII‐Fc), has been hypothesized to lower FVIII consumption in patients with severe Haemophilia A (pwSHA), without reducing clinical efficacy. What about real life?
Keywords:
haemophilia incentive;
incentive switch;
switch case;
severe haemophilia;
rfviii severe;
case high
Journal Title: European Journal of Clinical Investigation
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Clinical Investigation
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!